The hAMSC product is manufactured by the hospital's stem cell technology platform and has passed quality re-evaluation by the National Institutes for Food and Drug Control.The administration regimen is individualized and combined: intravenous infusion at a dose of 1.010 6 cells/kg and local intralesional injection at 2.010 4 cells/cm 2 of wound surface (Fig 3).Acute adverse events are closely monitored throughout treatment, with established emergency response protocols.Preliminary long-term follow-up data suggest that hAMSC therapy is both safe and effective.Conclusion: Based on these encouraging results, larger-scale, multicenter studies are warranted to validate the long-term efficacy and safety of hAMSC therapy.Future research should incorporate dynamic biomarker monitoring, optimize treatment protocols, strengthen multidisciplinary collaboration, and promote the standardized and precision-driven translation of stem cell therapies, ultimately establishing safer, more effective, and cost-efficient regenerative medicine approaches for patients.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Wang et al. (Wed,) studied this question.